4Suarez L, Vidriales MB, Moreno MJ, et al. Differences in antiapoptotic and muhidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. Haematologica 2005, 90(1): 54-59.
5Hirose M, Hosoi E, Hamano S, et al. Muhidrug resistance in hematological malignancy. J Med Invest, 2003, 50(3-4): 126-135.
6Yang CZ, Luan FJ, Xiong DS, et al. Multidrug resistance in leukemic cell line K562/A02 induced by doxorubicin. Acta Pharmacol Sin, 1995, 16(4): 333-337.
7Jimenez RE,Zalupski MM,Du W,et al.Multidrug resistance phenotype in high grade soft tissue sarcoma.Cancer,1999,86:976-981.
8Van ojik HH,Valerius T.Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy.Critical Reviews in Oncology/Hematology,2001,38:47-61.
9Koelemij R,Kuppen PJK,Van de velde CJH,et al.Bispecific antibody in cancer therapy,from the laboratory to the clinic.J Immunotherapy,1999,22:514-524.
10Fricker G,Miller DS.Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo.Pharmacol Toxicol,2002,90:5-13.
